Bloodborne biomolecular markers in prostate cancer development and progression

被引：39

作者：

Bok, RA ^{[1
]}

Small, EJ

机构：

[1] Univ Calif San Francisco, Dept Med, Urol Oncol Program, Ctr Comprehens Canc, San Francisco, CA 94143 USA

[2] Univ Calif San Francisco, Dept Urol, Urol Oncol Program, Ctr Comprehens Canc, San Francisco, CA 94143 USA

来源：

NATURE REVIEWS CANCER | 2002年 / 2卷 / 12期

关键词：

D O I：

10.1038/nrc951

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Prostate cancer is notoriously difficult to treat, which makes its early detection a priority. Biomarkers have been used to diagnose and monitor prostate cancer for more than 50 years, and the discovery of the serum marker prostate-specific antigen (PSA) significantly altered the detection and management of prostate cancer. But imperfect correlation with cancer hinders the usefulness of PSA. The elucidation and validation of new biological markers of prostate cancer should aid detection, and improve the application of the available therapeutics.

引用

页码：918 / 926

页数：9

共 92 条

[1]

Abrahamsson PA, 1999, PROSTATE, V39, P135, DOI 10.1002/(SICI)1097-0045(19990501)39:2<135::AID-PROS9>3.0.CO

[2]

2-S

[3]

Adam BL, 2002, CANCER RES, V62, P3609

[4] Prognostic factors for carcinoma of the prostate [J].

Altwein, JE ;

Luboldt, HJ .

UROLOGIA INTERNATIONALIS, 1999, 63 (01) :62-71

[5] Prognostic significance of neuroendocrine differentiation in prostate cancer [J].

Ather, MH ;

Abbas, F .

EUROPEAN UROLOGY, 2000, 38 (05) :535-542

[6]

Balbay M. D., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P225

[7]

Bangma CH, 2000, MICROSC RES TECHNIQ, V51, P430, DOI 10.1002/1097-0029(20001201)51:5<430::AID-JEMT5>3.0.CO

[8]

2-1

[9]

BARRETTCONNOR E, 1990, CANCER RES, V50, P169

[10]

BATTISTINI B, 1993, LAB INVEST, V68, P600

← 1 2 3 4 5 6 7 8 9 10 →